Charley Lu

36 Flips | 4 Magazines | 3 Likes | 3 Following | 1 Follower | @Char1eyLu | Precision Oncology | Immunoengineering | Machine Learning | Flips Are My Own

Trillium Acquires Privately-Held Fluorinov Pharma Inc.

• Proprietary industry-leading fluorine-based medicinal chemistry platform providing an internal engine to generate future programs<br>• Platform validated …

Business Development

Acorda to Acquire Biotie Therapies

• Obtains global rights to Phase 3 Parkinson’s disease treatment and additional clinical-stage assets<br>• Positions Acorda as a leader in Parkinson’s …

AstraZeneca and Moderna Therapeutics Announce New Collaboration to Co-Develop and Co-Commercialize Immuno-Oncology mRNA Therapeutics™

Moderna to lead preclinical development; AstraZeneca to lead clinical development; Moderna to co-commercialize and share profits on resulting …

Seres Inks Nestlé As Potential $2B Partner; Key Microbiome Data Soon

[<i>Updated, 1/11/16. Corrected, 1/20/16. See below</i>.] Microbiome company Seres Therapeutics (NASDAQ: MCRB) has inked a deal with one of its top …

Thermo Fisher Scientific to Acquire Affymetrix for $1.3B | GEN

Click Image To Enlarge +<p>Thermo Fisher says deal will strengthen its position in bioscience research tools and genetic analysis.<p>×<p>Thermo Fisher …

Financial Markets

Roche Acquires Tensha Therapeutics for $115M Upfront | GEN

Roche will acquire Tensha Therapeutics for an upfront cash payment of $115 million, plus additional contingent payments of up to $420 million.<p>Tensha, …

Cancer

Gilead to Invest $725 Million in Galapagos After AbbVie Snub

Gilead Sciences Inc. plans to pay $725 million to acquire a stake in Belgian drugmaker Galapagos NV and buy into an experimental drug that had been …

Mylan to Co-Develop Six Momenta Biosimilars in Up-to-$245M Alliance | GEN

Mylan said today it will partner with Momenta Pharmaceuticals to develop, manufacture, and commercialize six of Momenta’s current biosimilar …

Regulation

Complix | Complix Enters into Strategic Collaboration with Merck Inc, worth up to US$ 280 million

Complix Enters into Strategic Collaboration with Merck Inc, worth up to US$ 280 million<p>Posted at 09:00h in News by Complix<p>Complix Enters into …

Immunotherapy

Zoetis Selling Manufacturing Sites, Products to Huvepharma for $40M | GEN

Zoetis said today it will sell manufacturing sites in Laurinburg, NC, and Longmont, CO, to Huvepharma among cost-cutting moves that will generate $40 …

Manufacturing

Merck Co. Sells 2 NDAs to ANI Pharmaceuticals for $75M+ | GEN

Merck & Co. plans to sell the NDAs for purified corticotropin gel and corticotropin-zinc hydroxide to ANI Pharmaceuticals for $75 million cash and a …

MannKind, Sanofi End Licensing Pact for Diabetes Medicine Afrezza

Shares of Mannkind tumble 28% in early trading Tuesday<p>MannKind Corp. on Tuesday announced the termination of its licensing pact with Sanofi-Aventis in the U.S. for the development and sale of its inhaled insulin product Afrezza and signaled that it might look to sell the drug.<p>Shares of the company …

Licensing

Oncodesign Inks Drug Discovery Deal with BMS | GEN

Oncodesign entered into a strategic collaboration agreement with Bristol-Myers Squibb (BMS) to discover, develop, and commercialize novel macrocyclic …

Bristol-Myers Squibb

Press Release - Fibrocell

<b>Companies to Develop Best-in-Class Treatment for Arthritis and Related Conditions Through Targeted, Long-term Therapeutic Delivery While Sparing</b> …

Victorian Era

CRISPR

PRESS RELEASE<p>Bayer and CRISPR Therapeutics AG join Forces to Discover, Develop and Commercialize Potential Cures for Serious Genetic Diseases<p>The …

Oncology

Partnership aims to advance development of novel immune checkpoint therapies as Baxalta expands oncology leadership in orphan diseases. Symphogen to …

Biopharmaceutical

Hologic picks up DiagnoCure PCA3 prostate marker assets for $4.7m

DiagnoCure said last week it sold its PCA3 prostate cancer biomarker assets to Hologic‘s (NSDQ:HOLX) subsidiary Gen-Probe for $4.7 million (C$6.5 …

Prostate

Ligand to Acquire OMT, Inc., a Leader in Human Antibody Generation, for $178 Million in Cash and Stock

<i>Gains New Revenue Streams, 16 Fully-Funded Platform Partnerships and Licensees, Patent Portfolio and Potential Long-term Royalties from Human</i> …

Proforma

Why the Future Doesn't Need Us

From the moment I became involved in the creation of new technologies, their ethical dimensions have concerned me, but it was only in the autumn of …

Singularity

Facebook-like Network Analysis May Lead to Better Cancer Targeting | GEN

Click Image To Enlarge +<p>Interaction network highlighting the distribution of targets of approved cancer drugs (pink); targets of approved drugs from …

Cancer

How machine learning helps biologists crack life’s secrets

<i>This article is published in collaboration with The Conversation.</i><p>Once the three-billion-letter-long human genome was sequenced, we rushed into a new …

Machine Learning

Roche Partners with SQZ Biotech in $500M+ Cell Therapy Collaboration | GEN

Roche will partner with SQZ Biotech to develop a cell therapy platform that would empower a patient’s own immune cells to fight a broad range of …

Immune System

BioAtla Enters Into Strategic License And Option Agreement With Pfizer For A New Class Of Antibody Therapeutics

SAN DIEGO, Dec. 7, 2015 /PRNewswire/ -- BioAtla LLC, a biotechnology company focused on the development of Conditionally Active Biologic (CAB) …

Pieris Pharmaceuticals Announces First Cancer Immunotherapy Collaboration

Agreement With Roche Leverages Proprietary Anticalin(R) Technology Platform<p>BOSTON, MA -- (Marketwired) -- 12/08/15 -- <i>Pieris Pharmaceuticals, Inc.</i> …

Immune System

Zymeworks Announces Antibody Fc Engineering Collaboration and License Agreement with GSK | Zymeworks

Vancouver, Canada – Zymeworks Inc. today announced that it has entered into a collaboration and license agreement with GlaxoSmithKline (GSK) for the …

Antibodies